Moreover, preclinical data have indicated that thiazolidinediones and gliptins do not have beneficial effects, but gliptins, which increase GLP-1 levels in the brain, improve cognitive decline in individuals with diabetes [142]. The gene discussed is GCG; the disease is diabetes mellitus.